Medical Biological Laboratories Co., Ltd.

Sapporo Medical University

Shingo Toji

Noriyuki Sato

Tsuyoshi Saito

Toshihiko Torigoe

Yoshihiko Hirohashi

Hironori Otaka

Ryota Horibe

Kazue Nakano

Takuya Asano

Dongliang Li

Kazue Watanabe

Eri Atsuyama

The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

Tumor antigen peptide

A method has been developed to efficiently proliferate and culture a CTL specific to WT1 peptides under limiting dilution conditions. Utilizing this method, CTLs capable of recognizing both a state where a wildtype WT1 specific peptide is presented by HLA-A*24:02 and a state where a mutant WT1 specific peptide is presented by HLA-A*24:02 have been successfully obtained.

T cell receptor and uses thereof

Growing community of inventors

Nagano, Japan

Shingo Toji